IP Library Granted Patent US 12,048,706
Granted Patent B2
US 12,048,706 · App. 17/592,244 · Granted Jul 30, 2024

Methods of treating epilepsy or status epilepticus

Inventors: Kiran Reddy (Boston, MA); Stephen J. Kanes (Swarthmore, PA)
Assignee: Sage Therapeutics, Inc.
A61K31/573A61K31/57A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,048,706
App. No.
17/592,244
Granted
Jul 30, 2024
Kind
B2
Abstract

Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.

Claims (4)

1. A method of preparing a formulation comprising allopregnanolone, said method comprising the step of high shear mixing an aqueous 5 mg/mL solution of allopregnanolone with 25% sulfo butyl ether beta-cyclodextrin solution for a time period of one hour.

2. The method of claim 1 , wherein the step of high shear mixing is performed for a time period of one hour, characterized by a clear aqueous solution comprising 5 mg/mL allopregnanolone and 25% sulfo butyl ether beta-cyclodextrin.

3. The method of claim 1 , wherein the sulfo butyl ether beta-cyclodextrin includes a sulfo butyl ether beta-cyclodextrin salt.

4. The method of claim 1 , wherein the sulfo butyl ether beta-cyclodextrin includes a sulfo butyl ether beta-cyclodextrin sodium salt.

Assignments (2)
CHANGE OF NAME Recorded Aug 18, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075866/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2022
From: REDDY, KIRAN; KANES, STEPHEN JAY
To: SAGE THERAPEUTICS, INC.
Reel/Frame 061682/0576 →
Continuity (6)
Continuation 16419761 · May 22, 2019
Continuation 15940505 · Mar 29, 2018
Continuation 13972851 · Aug 21, 2013
Provisional Application 61789491 · Mar 15, 2013
Provisional Application 61691545 · Aug 21, 2012
Related Publication 20220152050A1 · May 19, 2022
Cited By (4)
US 12,358,942 US 12,473,327 US 12,534,495 US 12,655,175